Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites - PubMed (original) (raw)
Comparative Study
. 2013 Aug 28;169(3):377-82.
doi: 10.1530/EJE-13-0529. Print 2013 Sep.
Affiliations
- PMID: 23832865
- DOI: 10.1530/EJE-13-0529
Comparative Study
Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites
N van Duinen et al. Eur J Endocrinol. 2013.
Abstract
Context: A substantial number of patients with head and neck paragangliomas (HNPGLs) have biochemically active tumors, evidenced by increased urinary excretion of catecholamines and metabolites, including 3-methoxytyramine (3MT). It is unclear whether plasma levels of these parameters are more sensitive to detect biochemical activity in HNPGL patients than urinary excretion rates.
Objective: To compare plasma free levels vs urinary excretion rates of deconjugated 3MT and combined metanephrines (MNs) in patients with HNPGL.
Patients and methods: We included 124 consecutive patients with HNPGL for screening of catecholamine excess by measurement of 24-h urinary excretion rates of deconjugated (nor)metanephrine, (nor)epinephrine, dopamine, vanillylmandelic acid, 3MT, and plasma free levels of (nor)metanephrine and 3MT.
Results: Plasma free 3MT levels were increased in 35 of the 124 patients (28%), whereas 24-h urinary excretion of deconjugated 3MT was increased in 30 patients (24%) (P=0.13). Plasma free MN levels were increased in seven patients (6%) and urinary deconjugated MN levels in six patients (5%) (P=1.00). Plasma free normetanephrine (NMN) levels were increased in seven patients (6%), and five patients had increased urinary excretion of deconjugated NMN (4%) (P=0.69). Plasma free combined MN levels (NMN, MN, and 3MT) were increased in 41 patients (33%), whereas 24-h urinary excretion rates of deconjugated combined MNs were increased in 33 patients (27%, P<0.05).
Conclusions: The combined levels of free MNs and free 3MT in plasma indicate a higher number of biochemically active HNPGLs than the 24-h urinary excretion rates of these markers.
Similar articles
- Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas.
van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, Smit JW, Romijn JA, Corssmit EP. van Duinen N, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):209-14. doi: 10.1210/jc.2009-1632. Epub 2009 Nov 6. J Clin Endocrinol Metab. 2010. PMID: 19897674 - Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma.
Bílek R, Zelinka T, Vlček P, Dušková J, Michalský D, Novák K, Bešťák J, Widimský J Jr. Bílek R, et al. Physiol Res. 2015;64(Suppl 2):S313-22. doi: 10.33549/physiolres.933109. Physiol Res. 2015. PMID: 26680494 - Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors.
de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. de Jong WH, et al. J Clin Endocrinol Metab. 2009 Aug;94(8):2841-9. doi: 10.1210/jc.2009-0303. Epub 2009 Jun 30. J Clin Endocrinol Metab. 2009. PMID: 19567530 - Assessment of O-methylated catecholamine levels in plasma and urine for diagnosis of autonomic disorders.
Oeltmann T, Carson R, Shannon JR, Ketch T, Robertson D. Oeltmann T, et al. Auton Neurosci. 2004 Nov 30;116(1-2):1-10. doi: 10.1016/j.autneu.2004.08.013. Auton Neurosci. 2004. PMID: 15556832 Review. - Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
van Berkel A, Lenders JW, Timmers HJ. van Berkel A, et al. Eur J Endocrinol. 2014 Feb 4;170(3):R109-19. doi: 10.1530/EJE-13-0882. Print 2014 Mar. Eur J Endocrinol. 2014. PMID: 24347425 Review.
Cited by
- Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging.
Alrezk R, Suarez A, Tena I, Pacak K. Alrezk R, et al. Front Endocrinol (Lausanne). 2018 Nov 27;9:515. doi: 10.3389/fendo.2018.00515. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30538672 Free PMC article. Review. - Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades.
McCrary HC, Babajanian E, Calquin M, Carpenter P, Casazza G, Naumer A, Greenberg S, Kohlmann W, Cannon R, Monroe MM, Hunt JP, Buchmann L. McCrary HC, et al. JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):641-646. doi: 10.1001/jamaoto.2019.1110. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31194233 Free PMC article. - Nationwide study of patients with head and neck paragangliomas carrying SDHB germline mutations.
Rijken JA, Niemeijer ND, Leemans CR, Eijkelenkamp K, van der Horst-Schrivers ANA, van Berkel A, Timmers HJLM, Kunst HPM, Bisschop PHLT, van Dooren MF, Hes FJ, Jansen JC, Corssmit EPM, Hensen EF. Rijken JA, et al. BJS Open. 2018 Feb 6;2(2):62-69. doi: 10.1002/bjs5.39. eCollection 2018 Apr. BJS Open. 2018. PMID: 29951630 Free PMC article. - Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.
Martucci VL, Pacak K. Martucci VL, et al. Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15. Curr Probl Cancer. 2014. PMID: 24636754 Free PMC article. Review. No abstract available. - A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.
Guha A, Musil Z, Vicha A, Zelinka T, Pacak K, Astl J, Chovanec M. Guha A, et al. Neoplasma. 2019 Jun 29;66(5):671-680. doi: 10.4149/neo_2018_181208N933. Print 2019 Sep. Neoplasma. 2019. PMID: 31307198 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical